Table 5.
A list of the alterations novelly appeared or increased during the lenvatinib treatment and the drugs with estimating effects for the gene alterations in patients with PD at 4 weeks
| Gene | Variant_type | Indel_type | Mut_aa | Mut_nt | Patient_ID | Novelly detected or increased | Report | Evidence level | Drug | Estimating effects | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ARID1A | Indel | Insertion | A2027fs | C > CA | HG-12 | Increased | ARID1A oncogenic mutation | (CancerVar) | ATR inhibitors | Responsive | PMID:27958275 |
| EZH2 inhibitor | Responsive | PMID:25686104 | |||||||||
| PARP inhibitor | Responsive | PMID:26069190 | |||||||||
| CTNNB1 | SNV | G34V | G > T | HG-06 | Increased | CTNNB1 oncogenic mutation | (CancerVar) | Tankyrase inhibitor | Resistant | PMID:23539443 | |
| SNV | S33C | C > G | HG-12 | Increased | |||||||
| DDR2 | SNV | W778L | G > T | HG-06 | Novelly detected | DDR2 mutant | (CancerVar) | Dasatinib | Sensitive | PMID:22328973 | |
| ESR1 | SNV | R477* | C > T | HG-18 | Novelly detected | ESR1 oncogenic mutation | Late trials: CGI|(CancerVar) | Fluvestrant | Responsive | PMID:27269946 | |
| Late trials: CGI|(CancerVar) | Exemestane | Resistant | PMID:27269946 | ||||||||
| LEVEL_3A:OncoKB | AZD9496 | PMID:27986707|PMID:27269946|PMID:31563959 | |||||||||
| LEVEL_3A:OncoKB | Fulvestrant | PMID:27986707|PMID:27269946|PMID:31563959 | |||||||||
| TP53 | SNV | G245S | C > T | HG-06 | Increased | TP53 G245S | (CancerVar) | AMGMDS3 | Resistance | PMID:25730903 | |
| SNV | C238S | A > T | HG-18 | Novelly detected | TP53 oncogenic mutation | Early trials: CGI|(CancerVar) | Abemaciclib | Resistant | PMID:27217383 | ||
| Early trials: CGI|(CancerVar) | Cisplatin | Resistant | PMID:27646943 | ||||||||
| Early trials: CGI|(CancerVar) | AZD6738 | Responsive | NCT01955668|https://ash.confex.com/ash/2014/webprogram/Paper71027.html | ||||||||
| Early trials: CGI|(CancerVar) | Decitabine | Responsive | PMID:27959731 | ||||||||
| (CancerVar) | Doxorubicin | Responsive | PMID:27397505 | ||||||||
| Gemcitabine | Responsive | PMID:27397505 | |||||||||
| Mitomycin C | Responsive | PMID:27397505 | |||||||||
| WEE1 inhibitor | Responsive | PMID:25125259|PMID:27998224 | |||||||||
| MDM2 inhibitor | Resistant | PMID:23084521|ASCO 2015 (abstr 10,564) | |||||||||
| Pramlintide | Responsive | PMID:25409149 | |||||||||
| AR | SNV | R609K | G > A | HG-22 | Novelly detected | AR mutation | (CancerVar) | Nilutamide|Cyproterone Acetate|Flutamide|Bicalutamide | Resistance | PMID:26000489 | |
| ATM | SNV | R2832H | G > A | HG-22 | Increased | ATM R2832H | LEVEL_1:OncoKB | Olaparib | PMID:32343890 | ||
| ATM | SNV | G2891D | G > A | HG-22 | Novelly detected | ATM oncogenic mutation | Early trials: CGI|(CancerVar) | Cisplatin | Responsive | PMID:26238431 | |
| ATM | Early trials: CGI|(CancerVar) | Olaparib | Responsive | ENA 2014 (abstr 8LBA)|PMID:26510020 | |||||||
| ATM | (CancerVar) | ATR inhibitor | Responsive | ENA 2015 (abstr A48) | |||||||
| ATM | Indel | Insertion | S1905fs | T > TA | HG-22 | Increased | Temozolomide | Responsive | PMID:23960094 | ||
| ATM | DNA-PKc inhibitor | Responsive | PMID:23761041 | ||||||||
| ATM | PARP inhibitor | Responsive | ENA 2014 (abstr 8LBA) | ||||||||
| ATM | LEVEL_4:OncoKB | Olaparib | PMID:20739657|PMID:26510020 | ||||||||
| NFE2L2 | SNV | D29G | T > C | HG-12 | Novelly detected | ||||||
| TERT | SNV | C > G | HG-06 | Increased | |||||||
| SNV | G > A | HG-06 | Increased |